undamentalytics Newsletter
Sign in

Orthofix Medical Inc. (OFIX) stock

Add to watchlist

Add holding +

NASDAQ: OFIX Nasdaq Health Care Equipment Next results ~November 9, 2026

C+ Fundamentals grade

Orthofix Medical Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$21

Revenue-to-maturity cash-flow model

Base case. Range ~$18–$28 across our lower- and higher-growth cases (0%–8% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Orthofix Medical Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders5 buying, 9 selling18 purchases and 28 sales by directors and officers, last 12 monthsInsider trades
  • Funds82 adding, 65 cuttingOf 33 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Orthofix Medical files

Where Orthofix Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $833m, up 3.0% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin fell to -3.3% from -0.0% a year earlier. Operating margin widened to -4.7% from -11.8%. The diluted share count is up 3.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 5 financial-health checks. Our revenue-to-maturity cash-flow model value is $21.48 a share, against a share price of $10.54.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Orthofix Medical Inc.'s trailing-twelve-month revenue grew 3.0% year on year, with a free-cash-flow margin of -3.3%.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 14940.0% while net income grew 50.1%: a 14990pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 7.1 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -4.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -3.3% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 3.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 0.9 against the S&P 500.
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 56.0% over 90 days.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.07 against an average estimate of -$0.03: beat by 334.0%
Revenue
$211m, up 3.8% on a year earlier
Share reaction
-13.1% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 9, 2026; average EPS estimate $0.11

Orthofix Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.5%
  • 1 week-10.5%
  • 1 month-3.7%
  • This year-42.3%
  • 1 year-43.3%
  • 5 years-77.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$833M
Operating margin
-4.7%
Net margin
-7.4%
EPS (TTM, diluted)
$-1.53

Growth

Revenue growth
+3.0%
Change in growth rate
+0.4 pts
Share count change
+3.6%

Cash

Free cash flow (TTM)
-$27.8M
FCF margin
-3.3%
Stock pay % of revenue
3.4%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Orthofix Medical Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Orthofix Medical Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$21 ~$18–$28 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$20 ~$24–$100 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$21 ~$20–$21 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Orthofix Medical Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$39.21$36.18$54.70$52.49$46.18$42.98$31.09$20.53$13.48$17.46$15.16$8.75
Market value$737m$668m$1.0bn$993m$873m$833m$612m$412m$495m$666m$600m$352m
+ Net debt (− = net cash)−$64m−$40m−$81m−$70m−$70m$4m−$88m−$51m$61m$74m$75m$118m
Enterprise value$673m$628m$931m$923m$803m$837m$524m$361m$556m$740m$676m$470m
Multiples
Price / sales 1.9x1.6x2.3x2.2x1.9x2.1x1.3x0.9x0.7x0.8x0.7x0.4x
Price / earnings —n/m162.6x71.9x—n/m——————
Price / free cash flow 44.9x15.7x41.6x27.3x67.0x14.2xn/m—————
EV / EBITDA 22.3x15.0x15.3x18.9x135.8x34.5x24.6x22.9x———34.4x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

41 /100

Weak moat

How hard Orthofix Medical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -5.3% of total assets over 10 years.

  • Pricing power 17 / 20

    Gross margin has been a median 74.9%, moving by 4.6 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -3.0%; its worst year was -18.9%.

  • Cash conversion 6 / 20

    Free cash flow was positive in 5 of 10 years, at a median 2.3% of revenue.

  • Discipline 8 / 20

    The diluted share count rose 113.7% over five years; stock-based pay has been a median 3.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $211m and EPS of $0.11 (range $0.11 to $0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.41 −16% $851m +4%
Next $0.37 −10% $874m +3%

Next year's EPS estimate has moved −56.0% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +36.7% on 90 days ago. In the last 30 days, 1 analyst raised Orthofix Medical Inc.'s forecast and 0 cut it.

Consensus EPS forecast Orthofix Medical Inc., last 90 days
$0.20 $0.40 $0.60 $0.80 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.30 Current fiscal year, 60 days ago: $0.41 Current fiscal year, 30 days ago: $0.41 Current fiscal year, 7 days ago: $0.41 Current fiscal year, Now: $0.41 $0.41 Next fiscal year, 90 days ago: $0.84 Next fiscal year, 60 days ago: $0.37 Next fiscal year, 30 days ago: $0.37 Next fiscal year, 7 days ago: $0.37 Next fiscal year, Now: $0.37 $0.37

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.30$0.84
60 days ago $0.41$0.37
30 days ago $0.41$0.37
7 days ago $0.41$0.37
Now $0.41$0.37

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.03 $0.07 +334.0%
Mar 2026 −$0.29 −$0.11 +61.0%
Dec 2025 $0.41 $0.24 −42.7%
Sept 2025 $0.12 $0.20 +64.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy375%
Hold125%
Sell00%

Monthly trend

  1. Oct 20261214
  2. Sep 20261225
  3. Aug 20261225

Counts of recommendations published by analysts covering Orthofix Medical Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.6%
of tradable shares
Days to cover
5.61
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
2.2%
of shares
Employees
1,605
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −43.3%

$15.44 on October 31, 2025 to $8.75

ThenNowEffect
Revenue (last 12 months) $809m $833m +3.0%
P/S multiple 0.7x 0.4x −43.0%
Share count 39m 40m −3.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −28.7%

$12.28 on November 3, 2023 to $8.75

ThenNowEffect
Revenue (last 12 months) $598m $833m +39.2%
P/S multiple 0.6x 0.4x −26.9%
Share count 28m 40m −30.0%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OFIX−28%−34%−34%+30%−13%−42%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OFIX33%33%50%58%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OFIX−40%−60%−57%−20%−46%−47%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 87% from February 25, 2019 to September 17, 2026. Getting back needed a 684% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.64 – $16.20
From 52-week high
−46.0%
vs 50-day average
−6.5%
vs 200-day average
−21.0%
Volatility (1 year)
48%
Beta vs S&P 500
0.88

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±8.1%
After a week
6 up, 6 down
typical move ±8.2%
After a month
4 up, 8 down
typical move ±12.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −13.1% −0.4% −14.8% −23.7%
May 5, 2026 +1.5% +2.2% +1.4% −13.9%
April 9, 2026 +1.5% +0.5% +1.6% −4.5%
February 24, 2026 −4.0% +1.6% −4.1% −12.2%
November 4, 2025 −6.8% −0.8% −4.2% −1.0%
August 5, 2025 +15.6% +0.3% +27.2% +35.5%
May 6, 2025 −11.2% −0.4% −7.8% −20.9%
February 25, 2025 −4.9% −0.4% −6.3% −10.2%
November 7, 2024 +5.5% +1.2% −4.3% −0.7%
August 6, 2024 +13.8% +0.2% +6.5% +16.7%
May 7, 2024 +10.7% +0.1% +12.4% +0.6%
March 5, 2024 +8.1% −0.5% +7.5% +8.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Orthofix Medical Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Orthofix Medical Inc.
$650M $700M $750M $800M $850M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $668.5M Revenue (TTM), FY23 Q4: $746.6M Revenue (TTM), FY24 Q1: $760M Revenue (TTM), FY24 Q2: $771.6M Revenue (TTM), FY24 Q3: $784.2M Revenue (TTM), FY24 Q4: $799.5M Revenue (TTM), FY25 Q1: $804.5M Revenue (TTM), FY25 Q2: $809M Revenue (TTM), FY25 Q3: $818.1M Revenue (TTM), FY25 Q4: $822.3M Revenue (TTM), FY26 Q1: $825.4M Revenue (TTM), FY26 Q2: $833.2M $833.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $668.5M
FY23 Q4 $746.6M
FY24 Q1 $760M
FY24 Q2 $771.6M
FY24 Q3 $784.2M
FY24 Q4 $799.5M
FY25 Q1 $804.5M
FY25 Q2 $809M
FY25 Q3 $818.1M
FY25 Q4 $822.3M
FY26 Q1 $825.4M
FY26 Q2 $833.2M
Revenue growth, TTM YoY Orthofix Medical Inc.
0% 20% 40% 60% 80% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 44.2% Revenue growth, TTM YoY, FY23 Q4: 62.1% Revenue growth, TTM YoY, FY24 Q1: 43.5% Revenue growth, TTM YoY, FY24 Q2: 28.9% Revenue growth, TTM YoY, FY24 Q3: 17.3% Revenue growth, TTM YoY, FY24 Q4: 7.1% Revenue growth, TTM YoY, FY25 Q1: 5.9% Revenue growth, TTM YoY, FY25 Q2: 4.8% Revenue growth, TTM YoY, FY25 Q3: 4.3% Revenue growth, TTM YoY, FY25 Q4: 2.9% Revenue growth, TTM YoY, FY26 Q1: 2.6% Revenue growth, TTM YoY, FY26 Q2: 3.0% 3.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 44.2%
FY23 Q4 62.1%
FY24 Q1 43.5%
FY24 Q2 28.9%
FY24 Q3 17.3%
FY24 Q4 7.1%
FY25 Q1 5.9%
FY25 Q2 4.8%
FY25 Q3 4.3%
FY25 Q4 2.9%
FY26 Q1 2.6%
FY26 Q2 3.0%
Operating margin (TTM) Orthofix Medical Inc.
-20% -15% -10% -5% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -19.7% Operating margin (TTM), FY23 Q4: -18.6% Operating margin (TTM), FY24 Q1: -14.3% Operating margin (TTM), FY24 Q2: -12.6% Operating margin (TTM), FY24 Q3: -11.7% Operating margin (TTM), FY24 Q4: -10.6% Operating margin (TTM), FY25 Q1: -12.9% Operating margin (TTM), FY25 Q2: -11.8% Operating margin (TTM), FY25 Q3: -11.4% Operating margin (TTM), FY25 Q4: -9.9% Operating margin (TTM), FY26 Q1: -5.7% Operating margin (TTM), FY26 Q2: -4.7% -4.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -19.7%
FY23 Q4 -18.6%
FY24 Q1 -14.3%
FY24 Q2 -12.6%
FY24 Q3 -11.7%
FY24 Q4 -10.6%
FY25 Q1 -12.9%
FY25 Q2 -11.8%
FY25 Q3 -11.4%
FY25 Q4 -9.9%
FY26 Q1 -5.7%
FY26 Q2 -4.7%
FCF margin (TTM) Orthofix Medical Inc.
-15% -10% -5% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -13.1% FCF margin (TTM), FY23 Q4: -14.2% FCF margin (TTM), FY24 Q1: -11.8% FCF margin (TTM), FY24 Q2: -9.3% FCF margin (TTM), FY24 Q3: -5.7% FCF margin (TTM), FY24 Q4: -1.1% FCF margin (TTM), FY25 Q1: -0.6% FCF margin (TTM), FY25 Q2: -0.0% FCF margin (TTM), FY25 Q3: -0.5% FCF margin (TTM), FY25 Q4: -0.2% FCF margin (TTM), FY26 Q1: -0.5% FCF margin (TTM), FY26 Q2: -3.3% -3.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -13.1%
FY23 Q4 -14.2%
FY24 Q1 -11.8%
FY24 Q2 -9.3%
FY24 Q3 -5.7%
FY24 Q4 -1.1%
FY25 Q1 -0.6%
FY25 Q2 -0.0%
FY25 Q3 -0.5%
FY25 Q4 -0.2%
FY26 Q1 -0.5%
FY26 Q2 -3.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 546 463 436 440 398 402 396 410 434 453 460 407 464 461 747 799 822 833
Gross profit 407 365 339 339 291 303 310 322 341 356 359 305 350 337 486 546 566 594
EBITDA 86 88 30 93 12 40 30 42 61 49 6 24 21 16 −86 −25 −4 14
Operating income 64 66 7 75 −11 17 9 21 41 30 −19 −6 −8 −13 −139 −85 −81 −39
Net income 24 44 −18 43 −29 −9 −3 3 6 14 −28 3 −38 −20 −151 −126 −92 −62
Diluted EPS $1.42 $2.47 −$0.97 $2.21 −$1.54 −$0.46 −$0.15 $0.17 $0.34 $0.72 −$1.51 $0.13 −$1.95 −$0.98 −$4.12 −$3.30 −$2.33 −$1.53
Growth (year on year)
Revenue — −15.2% −5.8% +1.1% −9.7% +1.2% −1.4% +3.4% +5.9% +4.4% +1.5% −11.6% +14.2% −0.8% +62.1% +7.1% +2.9% +3.0%
EBITDA — +2.1% −66.2% +212.7% −87.5% +244.1% −24.6% +38.9% +45.4% −20.0% −87.9% — −12.3% −26.0% −646.3% — — —
Operating income — +3.3% −90.0% — −114.9% — −46.0% +127.6% +93.7% −26.3% −162.4% — — — — — — —
Net income — +81.0% −140.0% — −167.2% — — — — — −306.1% — — — — — — —
Diluted EPS — +73.9% −139.3% — −169.7% — — — — — −309.7% — — — — — — —
Margins
Gross margin 74.6% 79.0% 77.9% 77.1% 73.1% 75.4% 78.2% 78.6% 78.6% 78.7% 78.1% 74.9% 75.3% 73.2% 65.1% 68.3% 68.8% 71.3%
EBITDA margin 15.8% 19.0% 6.8% 21.2% 2.9% 9.9% 7.6% 10.2% 14.0% 10.8% 1.3% 6.0% 4.6% 3.4% −11.5% −3.1% −0.5% 1.6%
Operating margin 11.7% 14.3% 1.5% 17.0% −2.8% 4.3% 2.3% 5.1% 9.4% 6.6% −4.1% −1.5% −1.8% −2.9% −18.6% −10.6% −9.9% −4.7%
Net margin 4.5% 9.6% −4.1% 9.7% −7.2% −2.1% −0.7% 0.7% 1.4% 3.0% −6.2% 0.6% −8.3% −4.3% −20.3% −15.8% −11.2% −7.4%
Free-cash-flow margin 5.4% 3.6% 9.1% −4.1% 10.6% 8.2% 4.1% 10.4% 5.6% 8.0% 2.8% 14.5% 0.1% −7.1% −14.2% −1.1% −0.2% −3.3%
Cash flow
Cash from operations 51 42 65 10 67 51 44 59 39 50 32 74 18 −12 −46 26 33 16
Capital spending 21 26 25 28 25 18 27 16 15 14 19 15 18 21 60 35 35 44
Free cash flow 30 16 40 −18 42 33 16 43 24 36 13 59 1 −33 −106 −9 −1 −28
Stock-based pay 11 8 7 6 6 6 7 16 13 19 22 16 15 18 36 32 29 29
Free cash flow after stock pay 19 8 33 −24 36 27 9 27 12 17 −9 43 −15 −51 −142 −42 −30 −56
Balance sheet
Cash 13 14 33 31 29 37 64 40 81 70 70 96 88 51 33 83 82 104
Total debt 0 216 209 20 20 0 0 0 0 0 0 100 0 0 94 157 157 222
Net debt (negative = net cash) −13 203 176 −11 −9 −37 −64 −40 −81 −70 −70 4 −88 −51 61 74 75 118
Diluted shares 17m 18m 18m 19m 19m 18m 19m 18m 18m 19m 19m 19m 20m 20m 37m 38m 40m 40m
Returned to shareholders
Buybacks 0 — — — 39 — 12 63 — — — — — — — — — —
Total returned 0 — — — 39 — 12 63 — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $873m
Short-term assets $446mLonger-term assets $427m
What it owes, and who funded it · $873m
Short-term liabilities $157mLonger-term liabilities $287mShareholders' equity $429m
  • Short-term assets cover short-term liabilities $446m of assets due within a year against $157m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $446m short-term assets against $287m of longer-dated liabilities.
  • More cash than debt $104m of cash against $222m of debt.
  • Debt below 40% of shareholders' equity Debt is 52% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $16m of operating cash flow against $222m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Orthofix Medical Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+3.6%
year over year
R&D spending
7.4%
of revenue
Sales & admin spending
66.9%
of revenue
Days sales outstanding
59 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated OFIX ATEC IRTC MYGN VREX INSP Median
Revenue, last 12 months $833m $840m $825m $807m $865m $881m $99m
Revenue growth, last 12 months 3.0% 15.3% 25.6% −3.2% 5.3% −0.2% 9.2%
Revenue growth, 3-year average 11.7% 23.1% 22.2% 4.9% −1.2% 15.6% 13.5%
Revenue growth, latest quarter 3.8% 12.6% 20.1% −10.5% 3.7% −7.9% 10.2%
Gross margin 71.3% 71.3% 71.5% 68.8% 34.3% 86.2% 61.2%
Operating margin −4.7% −3.6% −3.0% −12.2% 8.3% 1.8% −8.5%
Operating margin, 3-year average −9.7% −14.8% −14.3% −27.2% 3.1% 2.6% −17.9%
Net margin −7.4% −10.3% −1.7% −14.0% 2.6% 11.4% −12.0%
Cash from operations / revenue 2.0% 7.3% 10.4% 1.0% 1.3% 15.3% −1.9%
Free-cash-flow margin −3.3% −1.2% 4.7% −4.2% −2.3% 11.1% −3.9%
Free-cash-flow margin, 3-year average −4.2% −12.1% −3.0% −10.5% 2.4% 9.1% −7.0%
Stock pay / revenue 3.4% 9.0% 10.1% 3.6% 1.7% 13.3% 6.1%
Change in share count 3.6% 4.6% 2.9% 2.5% −8.8% −3.9% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 3.0% 9.1% 95 of 129
Change in growth rate Growth +0.4pp -0.6pp 50 of 129
Gross margin Profitability 71.3% 61.9% 35 of 123
Operating margin Profitability -4.7% -8.3% 58 of 132
Net margin Profitability -7.4% -12.0% 57 of 133
Free-cash-flow margin Cash generation -3.3% -3.4% 63 of 128
Stock pay as % of revenue Cash generation 3.4% 6.1% 44 of 123
Long-term debt as % of assets Balance sheet 25.4% 24.2% 46 of 87
Change in share count Balance sheet 3.6% 3.3% 59 of 115
Days sales outstanding Balance sheet 59 days 57 days 67 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Global Spine $688M 83.6% ▲ 1.8%
Global Limb Reconstruction $135M 16.4% ▲ 8.4%
Geography
Region Revenue Share YoY
United States $684M 83.2% ▲ 1.7%
Outside the US $138M 16.8% ▲ 9.1%
Other Countries $76.7M 55.5% ▲ 15.6%
IT $22.3M 16.1% ▲ 6.1%
United Kingdom $13.3M 9.6% ▲ 19.2%
France $12M 8.7% ▼ 10.7%
Germany $9.1M 6.6% ▲ 1.1%
Brazil $4.8M 3.5% ▼ 15.3%

From Orthofix Medical Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$350M
Institutions reporting
140
Shares held vs prior quarter
▲ 6.3%
Positions opened / closed
23 / 27

Top buyers and sellers, Q2 2026: 82 institutions bought and 65 sold ; the biggest buyer was AQR Capital Management LLC (+698K shares) and the biggest seller Philosophy Capital Management LLC (−559K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Engine Capital Management, LP $41.8M 4.6M 11.9% ▲ 4.2%
Juniper Investment Company, LLC $40.6M 4.4M 11.6% ▲ 11.7%
Rubric Capital Management LP $34M 3.7M 9.7% 0.0%
Blackrock, Inc. $30.4M 3.3M 8.7% ▲ 3.7%
Paradigm Capital Management Inc $30.2M 3.3M 8.6% ▼ 0.1%
Armistice Capital, LLC $29.8M 3.3M 8.5% ▲ 20.9%
Vanguard Capital Management LLC $15.8M 1.7M 4.5% ▲ 4.6%
Geode Capital Management, LLC $9.6M 1.0M 2.7% ▲ 11.6%
State Street Corp $8.7M 953K 2.5% ▲ 5.0%
AQR Capital Management LLC $8.1M 887K 2.3% ▲ 369.2%
Acadian Asset Management LLC $8.1M 887K 2.3% ▲ 58.5%
Millennium Management LLC $7.9M 862K 2.2% ▼ 19.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Orthofix Medical Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $6.8M 18 trades by 5 insiders, last 12 months Insider sales History → $6.6M 28 trades by 9 insiders · 0% under pre-set plans
Net ▲ $218,951 net buying
Insider Date Trade Shares Price Value
Fisher Patrick President, Global Limb Recon October 1, 2026 Sell pre-set plan 150 $9.44 $1,416
Juniper Investment Company, Llc 10% owner September 21, 2026 Sell 190,000 $8.86 $1.7M
Bartholdson John A. 10% owner September 21, 2026 Buy 190,000 $8.86 $1.7M
Juniper Investment Company, Llc 10% owner September 18, 2026 Sell 120,000 $8.74 $1M
Bartholdson John A. 10% owner September 18, 2026 Buy 120,000 $8.74 $1M
Fisher Patrick President, Global Limb Recon September 1, 2026 Sell pre-set plan 150 $9.39 $1,408
Fisher Patrick President, Global Limb Recon August 18, 2026 Sell 1,295 $10.09 $13,067
Michas Alexis P 10% owner August 17, 2026 Sell 20,000 $10.01 $200,200
Michas Alexis P 10% owner August 14, 2026 Sell 19,500 $10.38 $202,410
Mcpherron Aviva Pres, Global Ops & Qual June 18, 2026 Sell 3,670 $9.38 $34,425
Juniper Investment Company, Llc 10% owner May 22, 2026 Sell 242,000 $10.70 $2.6M
Engine Jet Capital, L.P. 10% owner May 7, 2026 Buy 18,192 $12.20 $221,942

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 5, 2026
  • April 9, 2026
  • February 24, 2026
  • November 4, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Orthofix Medical Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Orthofix Medical Inc. in brief

What does Orthofix Medical Inc. do?
Orthofix Medical Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Orthofix Medical Inc.'s stock ticker?
Orthofix Medical Inc. trades under the ticker OFIX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Orthofix Medical Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Orthofix Medical Inc. reported revenue of $833M, 3.0% higher than a year earlier, according to its SEC filings.
What is Orthofix Medical Inc.'s free cash flow?
Orthofix Medical Inc.'s free-cash-flow margin is -3.3% of revenue over the trailing twelve months, ranking 63 of the 128 health care equipment companies we cover.
Who are Orthofix Medical Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Engine Capital Management, LP, Juniper Investment Company, LLC and Rubric Capital Management LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Orthofix Medical Inc.'s market cap?
On November 2, 2026, Orthofix Medical Inc.'s market capitalisation was about $352M and net debt of $118M. Market figures come from third-party market data and may be delayed.
How much debt does Orthofix Medical Inc. have?
Orthofix Medical Inc.'s debt-to-equity ratio is 51.6%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Orthofix Medical Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Orthofix Medical Inc. are Alphatec Holdings, Inc., Irhythm Holdings, Inc., Myriad Genetics Inc, Varex Imaging Corp and Inspire Medical Systems, Inc. The side-by-side comparison below sets their revenue, margins and growth against Orthofix Medical Inc.'s.
Are insiders buying or selling Orthofix Medical Inc. stock?
Over the last 12 months, Orthofix Medical Inc.'s directors and officers reported 18 open-market purchases and 28 sales on Form 4. The insider trading page charts every trade.
When is Orthofix Medical Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Orthofix Medical Inc. announces its own schedule.